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Background: Major depressive disorder (MDD) can be challenging to manage due its variable and epi-
sodic nature. Post hoc analyses were conducted on ﬁve studies (NCT00969709, NCT01377194,
NCT00969150, NCT01034462, EudraCT:2006-002404-34) to evaluate the efﬁcacy of levomilnacipran
extended-release (ER) in patients with different MDD episode histories.
Methods: Adults with MDD were randomized to double-blind treatment with levomilnacipran ER (40–
120 mg/d) or placebo. Three subgroups were identiﬁed: ﬁrst-episode (n¼494); highly recurrent (Z3
major depressive episodes; n¼1954); and chronic (current episode duration Z2 years; n¼218). Mean
changes from baseline to end of study (Week 8 [US studies], Week 10 [non-US study]) in Montgomery–
Åsberg Depression Rating Scale (MADRS), 17-item Hamilton Depression Rating Scale (HAMD17), and
Sheehan Disability Scale (SDS) total scores were analyzed in each subgroup. MADRS response, deﬁned as
Z50% total score improvement from baseline to Week 8/10, was also analyzed.
Results: Least squares mean differences (LSMDs) between treatment groups indicated signiﬁcantly
greater improvements with levomilnacipran ER versus placebo in MADRS (ﬁrst-episode, 2.5; highly
recurrent, 3.0; chronic, 4.9; all Po .05) and HAMD17 (ﬁrst-episode, 2.1; highly recurrent, 1.6;
chronic, 2.6; all Po .05) total scores. LSMDs for SDS total score were statistically signiﬁcant in the ﬁrst-
episode and highly recurrent MDD subgroups (both subgroups, 2.3; Po .01). MADRS response rate was
signiﬁcantly higher with levomilnacipran ER versus placebo in all three subgroups (ﬁrst-episode, 44.5%
versus 35.0%; highly recurrent, 44.3% versus 33.5%; 36.8% versus 22.0%; all Po .05).
Limitations: MDD subgroups were deﬁned post hoc; none of the studies were prospectively designed to
evaluate outcomes in these subgroups. Other limitations include lack of active comparators and varia-
bility of dose/duration due to data being pooled from multiple clinical trials.
Conclusions: Results suggest that levomilnacipran ER improves depression symptoms and functional
impairment in adult patients with different histories of MDD episodes.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
In patients with major depressive disorder (MDD), the primary
goals of initial treatment are to achieve symptom remission and
restore patient functioning to pre-illness levels (APA, 2013).
However, MDD can be challenging to manage due to the variable
and episodic nature of this disorder (Jefferson, 2011). Either psy-
chotherapy or pharmacologic treatment can be initiated in pa-
tients with mild-to-moderate MDD (APA, 2010). In patients with
severe depression, initiation of an approved pharmacotherapy is
strongly recommended, with treatment continuing for at leastB.V. This is an open access article u
and Institute for Women's
versity, Richmond, VA 23298,
.G. Kornstein).6 weeks at the maximum tolerated dose (Trivedi and Daly, 2008)
and medication selection based on the patient's clinical features
and medical history (APA, 2010). Effective management of MDD
also requires therapies that can successfully resolve symptoms and
improve functional impairment in patients with more chronic or
recurrent conditions, especially since previous depressive episodes
have been associated with greater disease burden and each suc-
cessive episode may further increase the risk of relapse or recur-
rence (Rush et al., 2012; APA, 2013). To reduce risk of relapse,
continuation of antidepressant therapy for 4–9 months may be
required; maintenance therapy is recommended in patients who
have chronic depression and in patients with Z3 prior major
depressive episodes (APA, 2010).
Levomilnacipran extended-release (ER) is a serotonin and
norepinephrine reuptake inhibitor (SNRI) that is currently ap-
proved for the treatment of MDD in adults (Forest, 2013). Fivender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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conducted to evaluate the efﬁcacy and safety of levomilnacipran
ER in adults with MDD (Asnis et al., 2013; Montgomery et al.,
2013; Bakish et al., 2014; Gommoll et al., 2014; Sambunaris et al.,
2014a). In all of these studies, the primary and secondary efﬁcacy
parameters were deﬁned as change from baseline in Montgomery-
Åsberg Depression Rating Scale (MADRS) and Sheehan Disability
Scale (SDS) total score, respectively. Previous post hoc analyses of
data from the ﬁve studies have shown that in the pooled Intent-to-
Treat (ITT) Population, patients who received levomilnacipran ER
versus placebo had signiﬁcantly greater improvements in both of
these measures (Sambunaris et al., 2014b; Montgomery et al.,
2015).
One of the previous post hoc analyses (Montgomery et al.,
2015) also found signiﬁcantly greater MADRS total score im-
provements and higher response rates (deﬁned as Z50% im-
provement in MADRS total score) with levomilnacipran ER relative
to placebo in both ﬁrst-episode and recurrent-episode patients, as
well as in patients with varying numbers of previous episodes (1–
2, 3–4, Z5). Similarly signiﬁcant ﬁndings were found in patients
with shorter current episode durations (o6 months, Z6 to o12
months) but not in patients with a longer episode duration (Z12
months). Building on these previously reported results, the current
post hoc analysis was conducted to further evaluate the effects of
levomilnacipran ER in patients with different depressive episode
histories. In contrast to the prior post hoc analysis, the current
analysis only focuses on three patient subgroups of clinical inter-
est: (1) MDD patients in their ﬁrst major depressive episode;
(2) patients with highly recurrent MDD, deﬁned as 3 or more
lifetime major depressive episodes; and (3) patients with chronic
MDD, deﬁned as current episode duration Z2 years.2. Methods
2.1. Studies
The ﬁve randomized, double-blind, placebo-controlled, multi-
center, clinical trials included in this post hoc analysis comprised
four US studies (Asnis et al., 2013; Bakish et al., 2014; Gommoll
et al., 2014; Sambunaris et al., 2014a) and one non-US study
(Montgomery et al., 2013); methods for all of these trials have
been previously published. Two studies evaluated the effects of
levomilnacipran ER at ﬁxed doses: 40, 80, or 120 mg/day (Asnis
et al., 2013); 40 or 80 mg/day (Bakish et al., 2014); both of these
were used for US Food and Drug Administration (FD) approval.
Three studies used a ﬂexible-dose design: 40–120 mg/day (Gom-
moll et al., 2014; Sambunaris et al., 2014a); 75–100 mg/day
(Montgomery et al., 2013); one of these studies (Sambunaris et al.,
2014a) was also used for FDA approval. The duration of double-
blind treatment was 8 weeks in the US studies and 10 weeks in the
non-US study.
2.2. Patients
The levomilnacipran ER clinical trials included men and wo-
men, Z18 years of age, with a Diagnostic and Statistical Manual of
Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR) diagnosis
of MDD who were in a current major depressive episode with a
duration of Z4 weeks (Montgomery et al., 2013; Gommoll et al.,
2014; Sambunaris et al., 2014a, 2014b), Z8 weeks (Asnis et al.,
2013), or Z6 weeks to 12 months (Bakish et al., 2014). Other key
eligibility criteria included: MADRS total score Z30 (Asnis et al.,
2013; Gommoll et al., 2014; Sambunaris et al., 2014a) or total score
Z26 (Bakish et al., 2014); Clinical Global Impressions-Severity
(CGI-S) score Z4 (Bakish et al., 2014); 17-Item HamiltonDepression Rating Scale (HAMD17) total score 422 (Montgomery
et al., 2013); and SDS total score Z10, with Z1 subscale score Z6
(Montgomery et al., 2013). Patients with a principal DSM-IV-TR
Axis I diagnosis other than MDD were not allowed to participate in
the studies. Other key exclusion criteria included history of non-
response to Z2 antidepressants (at adequate doses and treatment
duration) and signiﬁcant risk of suicide, as judged by the In-
vestigator and based on patient responses to the Columbia-Suicide
Severity Rating Scale or other formal assessment (e.g., score Z5
on MADRS item 10 [suicidal thoughts]).
2.3. Efﬁcacy measures
The 10-item MADRS (total score range, 0–60) and HAMD17
(total score range, 0–50) were both used to evaluate overall de-
pression symptom severity (Hamilton, 1960; Montgomery and
Asberg, 1979). The SDS (total score range, 0–30) was used to
measure functional impairment (Sheehan et al., 1996). In all of
these scales, a higher score indicates worse severity. A more de-
tailed description of these assessment tools is presented in Sup-
plementary File 1.
2.4. Post hoc analyses
Analyses were based on the pooled ITT Population, deﬁned as
all randomized patients who received Z1 dose of double-blind
study treatment and had Z1 postbaseline MADRS assessment. All
levomilnacipran ER dosage groups were pooled for the current
analyses.
The number of depressive episodes for each patient was re-
corded in all ﬁve studies; the four US studies also collected in-
formation about current episode duration. Three subgroups were
identiﬁed based on these available data: (1) ﬁrst-episode MDD,
deﬁned as all patients (treatment-naïve and previously treated)
who entered the study during their ﬁrst major depressive episode;
(2) highly recurrent MDD, deﬁned as all patients with Z3 lifetime
depressive episodes; and (3) chronic MDD, deﬁned as all patients
with a current episode duration Z2 years, with the cutoff based
on diagnostic criteria for persistent depressive disorder (APA,
2013). Although the ﬁrst-episode and highly recurrent MDD sub-
groups were mutually exclusive, the chronic MDD subgroup was
composed of patients from both of these subgroups. No statistical
testing between patient subgroups was conducted.
In order to evaluate the effects of levomilnacipran ER on overall
depression symptoms and functional impairment, least squares
mean (LSM) changes from baseline to end of study (Week 8 for US
studies, Week 10 for non-US study) in MADRS, HAMD17, and SDS
total scores were analyzed in all three MDD subgroups. The least
squares mean differences (LSMDs) between levomilnacipran ER
and placebo for these score changes were analyzed using an
analysis of covariance (ANCOVA) model that included study, site,
treatment, baseline MDD status (i.e., MDD subgroup), treatment-
by-baseline status interaction as factors and baseline score as a
covariate. Missing values were imputed using the last observation
carried forward (LOCF) approach.
The LSM change from baseline in MADRS total score was ana-
lyzed at each study visit (Weeks 1, 2, 4, 6, and 8) in all three MDD
subgroups to explore the time course of treatment effects. Based on
the LSMD at each study visit, analyses were conducted using a
mixed-effects model for repeated measures (MMRM) that included
study site, treatment, visit, treatment-by-visit interaction, baseline
score, and baseline score-by-visit interaction as covariates. Week 10
data from the non-US study were not included in this analysis.
Three different types of response were analyzed based on the
following criteria: (1) MADRS response, deﬁned as Z50% total
score improvement from baseline at end of treatment (Week 8/10)
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score r2 (“much improved” or “very much improved”) at end of
treatment; and (3) SDS response, deﬁned as a total score r12 and
all subscale scores r4 at end of treatment (Sheehan and Sheehan,
2008). MADRS remission was deﬁned as total score r10 at end of
treatment (Montgomery and Moller, 2009). Odds ratios (ORs) with
95% conﬁdence intervals (95% CIs) for response and remission
were analyzed using a logistic regression model with treatment
group and baseline score as explanatory values and the LOCF ap-
proach. A logistic regression model was also used to test for in-
teractions between patient characteristics and MADRS response in
all 3 MDD subgroups. Factors that were tested in each subgroup
were as follows: sex (men, women), age (o40, Z40 to r55
years, 455 years), and sex-by-age (men and women, ages o40,
Z40 to r55 years, and 455 years).3. Results
3.1. Patients
As previously reported (Sambunaris et al., 2014b; Montgomery
et al., 2015), baseline characteristics in the overall pooled ITT Po-
pulation (N¼2598) were generally similar between the placebo
and levomilnacipran ER groups. Demographics and baseline
characteristics were also generally similar between treatment
groups in the ﬁrst-episode MDD (n¼494), highly recurrent MDD
(n¼1954), and chronic MDD (n¼218) subgroups (Table 1). How-
ever, current episode mean duration was longer in the ﬁrst-epi-
sode MDD subgroup (overall mean, 33.5 months) than in the
highly recurrent MDD subgroup (10.7 months); mean duration in
the chronic MDD subgroup was 73.6 months. In the US studies,
25.9% (89/344) of ﬁrst-episode patients and 7.6% (129/1698) of
highly recurrent patients had a current MDD episode Z2 years.
The non-US study did not collect data on current episode duration.
3.2. Mean improvements
Improvements in depression symptoms were signiﬁcantly
greater with levomilnacipran ER versus placebo in all three MDD
subgroups, as shown by mean decreases in MADRS and HAMD17Table 1
Demographics and baseline characteristics.
First-Episode MDDa H
Placebo LVM ER P
n¼177 n¼317 n
Demographics
Age, years, mean (SD) 41.7 (13.2) 40.3 (13.0) 4
Women, n (%) 102 (57.6) 191 (60.3) 51
White, n (%) 144 (81.4) 242 (76.3) 6
BMI, kg/m2, mean (SD) 27.5 (5.2) 27.5 (5.3) 2
MDD history, mean (SD)
MDD duration, years 3.7 (6.2) 3.6 (6.3) 14
Number of episodes 1.0 (0.0) 1.0 (0.1) 4
Current episode durationd 28.6 (71.7) 36.3 (82.4) 11
Baseline scores, mean (SD)
MADRS total 33.7 (4.9) 34.5 (4.7) 3
HAMD17 total 24.6 (3.6) 25.1 (3.5) 2
SDS total 21.4 (4.3) 21.1 (4.8) 19
Abbreviations: BMI, body mass index; HAMD17, 17-Item Hamilton Depression Rating Sc
pression Rating Scale; MDD, major depressive disorder; SD, standard deviation; SDS, Sh
a Patients with no prior major depressive episodes.
b Patients with Z3 major depressive episodes; represents 99.8% of patients with an
c Patients with current episode duration Z2 years. Does not include patients from
d Data not collected in the non-US study.total scores (Fig. 1A and B). In both scales, the mean decrease with
placebo was lower in the chronic MDD subgroup than in the other
two subgroups.
In the ﬁrst-episode MDD subgroup, a signiﬁcant difference
between levomilnacipran ER and placebo in MADRS total score
change was detected at Week 4 of double-blind treatment and at
all subsequent study visits (Fig. 2). Signiﬁcant effects of levo-
milnacipran ER versus placebo on MADRS total score were de-
tected by Week 1 in the highly recurrent MDD subgroup and by
Week 2 in the chronic MDD subgroup.
Mean changes in SDS total score were numerically similar
across 3 subgroups, with statistical signiﬁcance in the ﬁrst-episode
and highly recurrent MDD subgroups (Fig. 1C).3.3. Response and remission
In all three MDD subgroups, the percentage of patients with
MADRS response was signiﬁcantly higher with levomilnacipran ER
than with placebo (Table 2). No signiﬁcant interaction for sex, age,
or sex-by-age was found in any subgroup (all P4 .10). Patients in
all three subgroups also had signiﬁcantly higher CGI-I response
rates with levomilnacipran ER versus placebo (Table 2). For both
the MADRS and CGI-I- responder analyses, ORs favoring levo-
milnacipran ER were similar in the ﬁrst-episode and highly re-
current MDD subgroups. The largest effects on MADRS response
(OR¼2.15 [95% CI, 1.14–4.06]) and CGI-I response (OR¼1.90 [95%
CI, 1.03–3.48]) were found in the chronic MDD subgroup.
Treatment with levomilnacipran ER versus placebo resulted in
signiﬁcantly higher SDS response rates in the highly recurrent and
chronic MDD subgroup, with the largest treatment effect for SDS
response found in the chronic MDD subgroup (OR¼2.47 [95% CI,
1.20–5.09]) (Table 2). A statistically signiﬁcant result for MADRS
remission was only found in the highly recurrent MDD subgroup
(Po .001). In patients with chronic MDD, the odds of MADRS re-
mission were approximately twice as high with levomilnacipran
ER as with placebo (OR¼2.15 [95% CI, 0.94–4.89]), but the result
was not statistically signiﬁcant.ighly Recurrent MDDb Chronic MDDc
lacebo LVM ER Placebo LVM ER
¼770 n¼1184 n¼82 n¼136
3.9 (12.6) 43.4 (12.8) 44.2 (13.3) 45.4 (12.5)
1 (66.4) 771 (65.1) 50 (61.0) 86 (63.2)
29 (81.8) 929 (78.5) 67 (81.7) 104 (76.5)
8.6 (5.5) 28.4 (5.5) 28.4 (5.3) 28.4 (5.7)
.3 (10.8) 13.9 (10.8) 15.6 (12.5) 15.5 (13.5)
.5 (4.5) 4.4 (5.8) 4.7 (4.1) 4.5 (4.7)
.5 (20.7) 10.1 (16.6) 67.4 (85.3) 77.4 (100.9)
3.5 (4.5) 33.7 (4.4) 36.2 (4.3) 36.6 (4.1)
3.7 (4.2) 23.8 (4.2) 23.6 (4.8) 24.4 (4.0)
.6 (5.4) 20.1 (5.5) 21.1 (4.6) 21.2 (5.5)
ale; LVM ER, levomilnacipran extended-release; MADRS, Montgomery–Åsberg De-
eehan Disability Scale.
y prior episode.
the non-US study.
Fig. 1. Mean changes from baseline to end of study (LOCF). First-episode MDD deﬁned as all patients with no prior major depressive episodes; highly recurrent MDD deﬁned
as all patients with Z3 major depressive episodes; chronic MDD deﬁned as patients with current episode duration Z2 years. End of study deﬁned as Week 8 in the US study
and Week 10 in the non-US study. *Po .05; **Po .01; ***Po .001 versus placebo. ER, extended release; HAMD17, 17-Item Hamilton Depression Rating Scale; LOCF, last
observation carried forward; LSM, least squares mean; LSMD, least squares mean difference between treatment groups; MADRS, Montgomery–Åsberg Depression Rating
Scale; MDD, major depressive disorder; SDS, Sheehan Disability Scale.
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Variability in the presentation of MDD symptoms and course of
illness has prompted ongoing interest in ﬁnding treatments that
may be effective across various subgroups of MDD patients. This
type of research has included analyses based on different types of
depression (Fava et al., 1997), sociodemographic characteristics
(Kornstein et al., 2010; Chou and Cheung, 2013), comorbid psy-
chiatric disorders (Howland et al., 2009), and depressive episode
history (Perahia et al., 2006). Using data from ﬁve randomized,
double-blind, placebo-controlled studies of levomilnacipran ER in
adults with MDD, a retroactive analyses was conducted to examine
treatment outcomes in patients with ﬁrst-episode MDD, highly
recurrent MDD, and chronic MDD. In each of these three sub-
groups, patients who received levomilnacipran ER versus placebo
had signiﬁcantly greater mean improvements in depressionsymptoms (MADRS and HAMD17 total score) and higher response
rates (MADRS, CGI-I). However, there were some differences be-
tween subgroups that may warrant closer attention when con-
sidering levomilnacipran ER as a treatment option. When inter-
preting the results presented in this report, it is also important to
note that although the ﬁrst-episode MDD and highly recurrent
MDD subgroups were mutually exclusive, the chronic MDD sub-
group included both ﬁrst-episode (n¼89) and highly recurrent
MDD patients (n¼129); the chronic MDD subgroup was also
smaller than the other 2 subgroups, which may have attenuated
some of the statistical analyses.
Consistent with post hoc analyses of other MDD trials (Dodd
et al., 2013; Barros et al., 2014), current episode duration was
longer in the ﬁrst-episode MDD subgroup than in the highly re-
current MDD subgroup, with approximately 25% of ﬁrst-episode
patients in the US studies having a current episode duration of Z2
Fig. 2. Mean changes in MADRS total score by study visits (MMRM). *Po .05;
***Po .001 versus placebo. ER, extended release; LSM, least squares mean; MADRS,
Montgomery–Åsberg Depression Rating Scale; MDD, major depressive disorder;
MMRM, mixed-effects model for repeated measures.
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levomilnacipran ER trials may have had considerable delays in
diagnosis and treatment and/or inadequate treatment after the
onset of their ﬁrst major depressive episode, point to an ongoing
problem of underrecognized and undertreated depression. Early
recognition and prompt initial treatment of MDD episodes remain
important therapeutic goals since longer durations of untreated
illness have been associated with lower rates of response and re-
mission, more recurring episodes, worse functional outcomes, and
increased hospitalizations, particularly in the ﬁrst episode (Ghio
et al., 2014, 2015).
Based on mean changes in MADRS total score at study visits,
depression symptom improvements occurred most rapidly in the
highly recurrent MDD subgroup. As might be expected in a clinical
trial population, these patients with Z3 major depressive epi-
sodes constituted the largest subgroup to be included in the cur-
rent analysis, representing 99.8% of all 1957 patients who had any
number of prior episodes. In this subgroup, a statistically sig-
niﬁcant separation between levomilnacipran ER and placebo for
MADRS total score change was found at Week 1. The detection of
rapid onset may have been partly due to the statistical power of
this large subgroup. However, presuming that patients in the
highly recurrent MDD subgroup had received prior antidepressanttreatment for MDD, it is also possible that they were more sensi-
tized to treatment than ﬁrst-episode patients. Such an effect was
demonstrated in a pilot study of healthy volunteers in which
quantitative electroencephalography (qEEG) showed neurophy-
siologic changes to be more rapid in subjects who had prior an-
tidepressant exposure than in antidepressant-naïve subjects
(Hunter et al., 2013). Since both groups in this blinded study also
underwent a placebo (i.e., “pill-taking”) run-in period, the qEEG
results were considered independent of a conditioned response.
However, as the authors of the qEEG study conceded for their
own results (Hunter et al., 2013), the potential effects of learning
and behavior on patients′ expectations of treatment outcomes
cannot be overlooked in the current analysis. Since all ﬁve levo-
milnacipran ER studies excluded patients who had failed Z2 prior
antidepressants after adequate dosing and treatment duration,
those who did receive prior treatment might have had favorable
experiences that may have augmented their responsivity to cur-
rent treatment. Prior antidepressant history should therefore be
considered when counseling patients about initiating anti-
depressant therapy, both in multiple-episode patients who may
have positive or negative expectations about treatment based on
previous experiences and in ﬁrst-episode patients who may ben-
eﬁt from knowing that they might not experience symptom im-
provement for several weeks.
Although the onset of depression symptom improvement was
more rapid in highly recurrent patients than in ﬁrst-episode pa-
tients, both subgroups had similar rates of MADRS and CGI-I re-
sponse at end of treatment along with similar and statistically
signiﬁcant ORs favoring levomilnacipran ER over placebo. The
highly recurrent and ﬁrst-episode MDD subgroups also had sta-
tistically signiﬁcant end-of-treatment improvements in MADRS
and HAMD17 total scores. These ﬁndings, which are consistent
with other studies that have shown response rates and mean
symptom improvements to be unrelated to the number of pre-
vious episodes (Perahia et al., 2006; Dodd et al., 2013), underscore
the importance of allowing for an adequate treatment duration in
ﬁrst-episode patients before drawing conclusions about anti-
depressant efﬁcacy.
Mean improvements in SDS total score change were statisti-
cally greater with levomilnacipran ER versus placebo in the ﬁrst-
episode and highly recurrent MDD subgroups, although neither
SDS response nor MADRS remission was signiﬁcant in the ﬁrst-
episode MDD subgroup. Given the relatively slower onset of
treatment effect in ﬁrst-episode MDD subgroup, these results are
not entirely surprising since improvements in functional dys-
function usually lag behind the reduction of depression symptoms
(McKnight and Kashdan, 2009) and time to remission is generally
longer than time to response. However, the mean improvement in
SDS total score, both with placebo and levomilnacipran ER, was
larger in the ﬁrst-episode MDD subgroup than in the other two
subgroups, which suggests that functional impairments may have
been less entrenched in the ﬁrst-episode patients. Functional im-
pairment may be partly attributed to learned behaviors, and the
bidirectional relationship between psychosocial functioning and
depressive symptoms means that worsening in one domain is
often accompanied by worsening in the other (McKnight and
Kashdan, 2009). Strategies that improve patient functioning, in-
cluding both pharmacologic and nonpharmacologic therapies, are
therefore an important aspect in the clinical management of MDD.
Patients who entered the studies with a current episode
duration of Z2 years did not have markedly greater depression
symptoms or functional impairments relative to the other sub-
groups, as indicated by mean baseline MADRS, HAMD17, and SDS
total scores. However, post hoc analyses of other MDD trials have
shown that longer episode duration (433 weeks versus r33
weeks) is associated with signiﬁcantly worse symptom severity at
Table 2
Response and remission at end of study (LOCF).a
First-Episode MDDb Highly Recurrent MDDc Chronic MDDd
Placebo LVM ER Placebo LVM ER Placebo LVM ER
MADRS response
Patients, ne 177 317 770 1184 82 136
Responders, n (%) 62 (35.0) 141 (44.5) 258 (33.5) 525 (44.3) 18 (22.0) 50 (36.8)
Odds ratio (95% CI) 1.56 (1.06, 2.30) 1.63 (1.34, 1.97) 2.15 (1.14, 4.06)
P value 0.023 o0.001 0.018
CGI-I response
Patients, ne 174 315 582 812 82 136
Responders, n (%) 70 (40.2) 158 (50.2) 233 (38.3) 396 (48.8) 22 (26.8) 54 (39.7)
Odds ratio (95% CI) 1.53 (1.05, 2.25) 1.55 (1.25, 1.93) 1.90 (1.03, 3.48)
P value 0.027 o0.001 0.039
SDS response
Patients, ne 160 284 648 962 74 119
Responders, n (%) 61 (38.1) 126 (44.4) 235 (36.3) 461 (47.9) 13 (17.6) 40 (33.6)
Odds ratio (95% CI) 1.23 (0.81, 1.86) 1.76 (1.43, 2.18) 2.47 (1.20, 5.09)
P value 0.333 o0.001 0.014
MADRS remission
Patients, ne 177 317 770 1184 82 136
Remitters, n (%) 37 (20.9) 77 (24.3) 165 (21.4) 329 (27.8) 9 (11.0) 27 (19.9)
Odds ratio (95% CI) 1.33 (0.84, 2.09) 1.47 (1.18, 1.82) 2.15 (0.94, 4.89)
P value 0.224 o0.001 0.069
Abbreviations: CGI-I, Clinical Global Impresssions-Improvement; CI, conﬁdence interval; LVM ER, levomilnacipran extended-release; LOCF, last observation carried forward;
MADRS, Montgomery–Åsberg Depression Rating Scale; MDD, major depressive disorder; SDS, Sheehan Disability Scale.
a End of study deﬁned as Week 8 in the US studies and Week 10 in the non-US study.
b Patients with no prior major depressive episodes.
c Patients with Z3 major depressive episodes; represents 99.8% of patients with any prior episode.
d Patients with current episode duration Z2 years. Does not include patients from the non-US study.
e Number of patients with available assessments for the analysis.
S.G. Kornstein et al. / Journal of Affective Disorders 193 (2016) 137–143142baseline (Perahia et al., 2006) and that patients with a current
episode duration of 42 years have signiﬁcantly worse overall
disease severity and greater social disadvantages (e.g., employ-
ment status, income, health insurance) than patients with re-
current episodes (Rush et al., 2012). It is possible, therefore, that
the chronic MDD subgroup represented a patient population that
was particularly challenging to treat, which might not be reﬂected
in the mean baseline scores found in this analysis, but is consistent
with the lower rates of response (MADRS, CGI-I, and SDS) and
remission (MADRS) found in this subgroup as compared with the
other 2 subgroups. It is important to note, however, that the ORs
for all of these outcomes were larger in the chronic MDD subgroup
than in the other subgroups. The odds of a favorable result in
chronic MDD patients was twice greater with levomilnacipran ER
than placebo for MADRS and SDS response (both Po .05) and
MADRS remission although this outcome was not statistically
signiﬁcant (P¼ .069), which may have been partially due to the
small size of the chronic MDD subgroup (n¼218).
One potential explanation for these large ORs is that placebo
effects were diminished in chronic MDD patients (Papakostas
et al., 2015), as indicated by the smaller mean score changes and
lower response rates found with placebo in this subgroup as
compared with the other 2 subgroups. This diminished placebo
effect in the chronic MDD subgroup appears to have resulted in
large mean differences between levomilnacipran ER and placebo
in MADRS and HAMD17 total score changes (4.9 and 2.6, re-
spectively; both Po .05) and high ORs for MADRS, CGI-I, and SDS
response (2.15, 1.90, and 2.47, respectively; all Po .05). It is worth
mentioning that these chronic MDD subgroup results were rather
unexpected given the ﬁndings from a previous post hoc analysis
(Montgomery et al., 2015). In that analysis, patients with a current
episode duration Z12 months were found to have numerically
favorable but statistically nonsigniﬁcant differences between le-
vomilnacipran ER and placebo for change in MADRS total score
and MADRS response. In contrast, these outcomes were statisti-
cally signiﬁcant in patients with shorter episode durations (o6months and Z6 to o12 months). Taken together, the current and
previous post hoc analyses suggest that episode chronicity may
have a variable effect on treatment outcomes, although more de-
tailed analyses would be needed to better elucidate the relation-
ship between current episode duration and the efﬁcacy of levo-
milnacipran ER in MDD patients.
Interaction analyses conducted in each MDD subgroup in-
dicated no signiﬁcant effects of sex, age, or sex-by-age on MADRS
response. Other studies have suggested that hormonal changes in
older women may decrease antidepressant effects of SSRIs, which
may be corrected with hormone replacement therapy (Thase et al.,
2005), whereas antidepressant effects of SNRIs are more con-
sistent regardless of sex, age, and hormone therapy. In the present
analysis, the ORs for MADRS response (with no adjustment for
hormonal treatment) were greater in older women (455 years)
than in younger women (o40 years, Z40 to 55 years) in both the
single-episode and highly recurrent MDD subgroups although
differences among the subgroups were not statistically signiﬁcant.
These results were not entirely surprising since the previous post
hoc analysis (Montgomery et al., 2015) found that older patients
(Z60 years) had greater mean improvements in MADRS total
score and a lower number needed to treat for MADRS response
than younger patients (r45 years, Z45 to o60 years).
4.1. Limitations
The MDD subgroups analyzed in this report were deﬁned post
hoc and were based on patient-reported histories that had been
collected during the individual levomilnacipran ER trials. The
analyses required retroactive assessment of patients' episode his-
tories, and current episode duration was not available for the the
non-US study. A prospective analysis using more formal methods
for documenting the number of major depressive episodes and
episode duration might have resulted in different outcomes. Be-
cause the studies excluded patients who had previously failed Z2
prior antidepressants at adequate dosages and duration, the
S.G. Kornstein et al. / Journal of Affective Disorders 193 (2016) 137–143 143patients included in this analysis may have represented a popu-
lation that was more responsive to treatment. The generalizability
of these results to a broader clinical population are also limited by
other entry criteria, such as the exclusion of patients with co-
morbid major psychiatric illnesses. Given the negative impact of
psychiatric and medical comorbidities on episode duration (Gil-
mer et al., 2005; Sung et al., 2012), ongoing research is needed to
further explore the effects of levomilnacipran ER and other anti-
depressants on MDD patients with major concurrent illnesses. The
potential effects of prior antidepressant use on treatment out-
comes had initially been identiﬁed as an area of interest for the
post hoc analysis, but only 152 antidepressant-naïve patients were
identiﬁed in the levomilnacipran ER studies and it was decided
that the current analysis should focus on the larger ﬁrst-episode
MDD subgroup; future research in the antidepressant-naïve pa-
tients may be warranted. Finally, although data from these ﬁve
studies provide information about the acute effects of levomilna-
cipran ER in adult patients with different MDD episode histories,
longer clinical trials are needed to evaluate the potential beneﬁts
of this medication as a maintenance therapy in patients with re-
current or chronic MDD. The analyses presented in this report do
not provide adequate data to evaluate whether or not mean im-
provements and treatment response would be sustained during
longer treatment.5. Conclusions
Treatment with levomilnacipran ER versus placebo resulted in
signiﬁcantly greater depression symptom improvement and
higher MADRS and CGI-I response rates in ﬁrst-episode patients,
patients with Z3 major depressive episodes, and patients with a
current episode duration Z2 years. The most pronounced effects
were found in the chronic MDD subgroup, which consisted en-
tirely of ﬁrst-episode patients (40.8%) and highly recurrent pa-
tients (59.2%). Episode chronicity may be therefore be an im-
portant factor to consider when counseling patients about various
treatment options. The most consistent treatment effects were
found in patients with multiple depressive episodes, who con-
stituted the largest subgroup in this analysis. All outcomes in this
highly recurrent MDD subgroup were statistically greater with
levomilnacipran ER versus placebo, including SDS total score im-
provement, SDS response, and MADRS remission.Appendix A. Supplementary material
Supplementary data associated with this article can be found in
the online version at http://dx.doi.org/10.1016/j.jad.2015.12.058.References
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